Clinical trial
Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected…
NCT00323830 · Samsung Medical Center, Other · Completed
Key facts
| NCT number | NCT00323830 |
|---|---|
| Title | Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric Adenocarcinoma |
| Official title | Phase III Randomized Controlled Trial of Adjuvant Capecitabine/Cisplatin Chemotherapy and Chemoradiation Therapy for Gastric Adenocarcinoma |
| Lead sponsor | Samsung Medical Center, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gastric Cancer, Surgery |
| Intervention type | Drug |
| Interventions | Capecitabine, cisplatin, Radiotherapy (+/-) |
| Enrollment | 458 |
| Start date | Oct 1, 2004 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2011 |
| First posted | May 10, 2006 |
| Last update posted | Nov 9, 2011 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: